Recent advances in multiple myeloma: a Korean perspective.
- Author:
Junshik HONG
1
;
Jae Hoon LEE
Author Information
- Publication Type:Review
- Keywords: Multiple myeloma; Korea; Diagnosis; Neoplasm staging; Epidemiology
- MeSH: Aging; Anemia; Asian Continental Ancestry Group; Cytogenetics; Diagnosis; Epidemiology; Humans; Incidence; Korea; Multiple Myeloma*; Neoplasm Staging; Pathology, Molecular; Plasma Cells; Renal Insufficiency
- From:The Korean Journal of Internal Medicine 2016;31(5):820-834
- CountryRepublic of Korea
- Language:English
- Abstract: Epidemiologically, multiple myeloma (MM) is a malignant disorder of plasma cells with a higher incidence among Western populations than among Asians. However, there is growing evidence of a recent increase in the age-standardized incidence rate (ASR) of MM in Asian countries, particularly Korea. Application of novel agents has resulted in significant improvement of treatment outcomes, and the advances are ongoing with the recent introduction and U.S. Food and Drug Administration’s approval of newer agents, including carfilzomib, ixazomib, elotuzumab, and daratumumab. In concert with the technical advances in the cytogenetic and molecular diagnostics of MM, modifications of its diagnosis and staging system have been attempted for better risk stratification. The modified diagnostic criteria from the International Myeloma Working Group in 2014 enabled a strategy of more active treatment for some patients with smoldering MM, with an ultra-high risk of progression, and fine-tuned the definition of end-organ damage, known as CRAB (hypercalcemia, renal insufficiency, anemia, and bone lesions). Considering Korea’s trend of aging at an unprecedented rate, we can expect that the ASR of MM will maintain a gradual increase for many years to come; therefore, MM will be a cancer of critical importance from both medical and socioeconomic perspectives in Korea.
